• Explore /
  • Poster
  • / MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

Abstract Video & Slides Poster

Authors

null

Loretta J. Nastoupil

MD Anderson Cancer Center, Houston, TX

Loretta J. Nastoupil , Yuqin Song , Laurie Helen Sehn , Clémentine Sarkozy , Pier Luigi Zinzani , Antonio Salar Silvestre , Jun Zhang , Sha Huang , Julie Wang , Richard Delarue , Judith Trotman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT05100862

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS7590)

DOI

10.1200/JCO.2023.41.16_suppl.TPS7590

Abstract #

TPS7590

Poster Bd #

135a

Abstract Disclosures

Similar Posters

First Author: Anthony Mato

First Author: Laurie Helen Sehn

First Author: Umberto Vitolo

First Author: Ian W. Flinn